Navigation Links
Novel approach estimates nanoparticles in environment
Date:5/20/2009

DURHAM, N.C. Without knowing how much of an industrial chemical is being produced, it is almost impossible for scientists to determine if it poses any threat to the environment or human health.

Civil engineers at Duke University believe they have come up with a novel way of estimating how much of one such material titanium dioxide is being generated, laying the groundwork for future studies to assess any possible risks.

This information is especially valuable if the chemicals are in the form of nano-particles, which possess unique properties because of their miniscule size. Nanoparticles are attractive for a wide range of products, little is known about their consequences in the environment. One of the most widely used is the nanoparticle form of titanium dioxide, which can be found in such diverse products as sunscreens and toothpaste to paints and papers. It is also used in water treatment.

"The biggest problem we face in trying to determine any risks of titanium dioxide nanoparticles is that no one really knows how much of it there is," said Christine Robichaud, graduate student in civil and environmental engineering at Duke's Pratt School of Engineering. The results of her analysis were published online in the Journal of Environmental Science and Technology.

Robichaud found it especially difficult trying to collect this data, since the companies that process titanium dioxide were not willing to reveal information they deemed proprietary. So she used a novel approach developed by collaborators Lynne Zucker and Michael Darby at the University of California Los Angeles to estimate the rate of innovation in the biotechnology industry.

"We combined science and engineering knowledge with business and economic modeling to come up with what we think is the maximum amount of titanium dioxide nanoparticles out there," Robichaud said. "By taking the amount of bulk titanium dioxide produced, which is better underst
'/>"/>

Contact: Richard Merritt
richard.merritt@duke.edu
91-906-608-414
Duke University
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
2. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
3. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
4. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
5. Novel therapy may prove effective in treatment of 30 percent of cancers
6. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
7. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
8. Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
9. Novel gene predicts local recurrence in early onset breast cancer
10. Novel gene predicts local recurrence in early-onset breast cancer
11. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel approach estimates nanoparticles in environment
Novel approach estimates nanoparticles in environment
Other Medicine News:Health News:Children's Hospital Campus to be Renamed Thanks to Transformational Capital Gift 2Health News:Children's Hospital Campus to be Renamed Thanks to Transformational Capital Gift 3Health News:Children's Hospital Campus to be Renamed Thanks to Transformational Capital Gift 4Health News:Novel toxin receptor discovered for ulcer-causing stomach pathogen 2Health News:Novel toxin receptor discovered for ulcer-causing stomach pathogen 3Health News:PA ABC Will Benefit Commonwealth's Small Businesses, DCED Secretary Says 2Health News:Cold Spring Harbor scientists reveal a protein's role in enabling AIDS virus to reproduce 2Health News:Cold Spring Harbor scientists reveal a protein's role in enabling AIDS virus to reproduce 3Health News:Cold Spring Harbor scientists reveal a protein's role in enabling AIDS virus to reproduce 4Health News:Saint Joseph's Hospital of Atlanta Sued Over Patient Admission and Billing Scheme, According to Page Perry, LLC 2Health News:Lupus Community Rallies Behind Fiancee With Lupus in 'Race to the Altar' 2
Breaking Medicine Technology:ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Drinking Your Way to Health 3F Perhaps Not 59700 1Drinking Your Way to Health 3F Perhaps Not 59700 2Drinking Your Way to Health 3F Perhaps Not 59700 3UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 1UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 2UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 3UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 4UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 5UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 6UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 7UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 8UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 9UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 10UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 11UCBs Cimzia 28R 29 28certolizumab pegol 29 Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid A 14516 12Video Games Can Play Havoc With Kids Joints 59696 1Video Games Can Play Havoc With Kids Joints 59696 2Video Games Can Play Havoc With Kids Joints 59696 3